
|Videos|February 27, 2017
Targeting Beyond PD-1 in Melanoma
Author(s)Michael A. Postow, MD
Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses targets beyond PD-1 in melanoma.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
2
Safusidenib Shows Durable Responses in IDH1-Mutant Glioma at 3-Year Follow-Up
3
CheckMate 9LA Data Push Toward Dual Checkpoint Blockade in PD-L1–Negative NSCLC
4
Thoracic Radiotherapy Added to Atezolizumab Raised Toxicity in SCLC
5



























